Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® Vaccine Approximately Three Years Following Initial Vaccination in Adults Who Participated in Trial MTA29

NCT01239043 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01239043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01239043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® Vaccine Approximately Three Years Following Initial Vaccination in Adults Who Participated in Trial MTA29
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
February 29, 2012
Enrollment
139 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

meningitis, meningococcal infections, meningococcal meningitis